Scientists test revolutionary immune therapy to stop blood cancer before it strikes

This study is testing whether a CAR-T cell therapy called cilta-cel can safely treat people with high-risk smoldering myeloma, an early stage of blood cancer that hasn't yet caused symptoms. Researchers are giving 20 participants this immune therapy, which involves modifying their own T-cells to attack cancer cells, to see if it can control the disease early. The goal is to prevent progression to active multiple myeloma while monitoring for side effects over a 15-year follow-up period.